Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk...

Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )

ASH 2020: Targeted therapies in r/r multiple myeloma

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar

ASH 2020: Targeted therapies in r/r multiple myeloma ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar )

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve...

Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings ( Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA )

Treating acute leukaemias of ambiguous lineage

Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research...

Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including...

Dr Shaji Kumar and Dr Wenming Chen

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the...

Dr Jorge Cortes - Augusta University, Augusta, USA

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

$Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )$

More from ecancer